FDA press release
December 12, 2025 — The US Food and Drug Administration (FDA) approved two new oral medicines to treat gonorrhea – Nuzolvence (zoliflodacin) and Blujepa (gepotidacin).
Nuzolvence (zoliflodacin) granules dissolve in water. The medicine can treat uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 pounds.
Blujepa (gepotidacin) oral tablets are approved for the same condition in patients 12 years and older who weigh at least 99 pounds. The medicine is for patients who have few or no other treatment choices because of limited clinical safety data. Blujepa was first approved in March 2025 to treat urinary tract infections.
Read the full press release here.
SEE ALSO:
- Health Policy Watch: FDA approves first new gonorrhoea treatment in decades amid rising antibiotic resistance
- GSK press release: Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea
Source : FDA
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.